Introduction (Covering Core User Needs: Pain Points & Solutions):
Global Leading Market Research Publisher QYResearch announces the release of its latest report “18F-FDG (Fluorodeoxyglucose) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 18F-FDG (Fluorodeoxyglucose) market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nuclear medicine physicians, oncologists, and radiologists, accurate tumor detection, staging, and treatment monitoring are essential for patient management. Traditional anatomical imaging (CT, MRI) cannot reliably distinguish malignant from benign lesions or assess metabolic activity. 18F-FDG (Fluorodeoxyglucose) is a positron-emitting radiopharmaceutical that contains no carrier and radioactive 2-deoxy-2-fluoro-D-glucose. It can be combined with positron emission tomography (PET) for diagnostic purposes. It is administered by intravenous injection. Glucose is one of the metabolic energy substances of the human body. Malignant tumor cells have a strong metabolism and metabolize glucose much more than normal cells. The radionuclide fluorine [18F] is labeled on deoxy sugar (DG), and its properties are basically the same as glucose and participate in cell metabolism. Using PET-CT to capture the 18F-FDG sugar metabolism of human tissue can detect the activity of tumor cells. As the most widely used PET radiopharmaceutical, 18F-FDG enables functional imaging of glucose metabolism, providing critical information for oncology, cardiology, and neurology.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/releases/6093404/18f-fdg–fluorodeoxyglucose
1. Market Sizing & Growth Trajectory (With 2026–2032 Forecasts)
According to QYResearch’s proprietary market data, the global market for 18F-FDG (Fluorodeoxyglucose) was valued at US$822 million in 2025 and is projected to reach US$1,820 million by 2032, growing at a CAGR of 12.2% from 2026 to 2032. This strong growth is driven by three converging factors: (1) increasing PET-CT installations worldwide, (2) expanding oncology applications (cancer detection, staging, restaging, therapy monitoring), and (3) growing adoption in China and emerging markets. As China’s medical level improves, the number of PET-CT equipment will continue to increase, thereby further releasing the demand for 18F-FDG.
By concentration type, normal concentration (0.37-0.74 GBq/ml) dominates with approximately 50% of market revenue (standard oncology imaging). High concentration (0.74-1.5 GBq/ml) accounts for 30%, and ultra-high concentration (1.5-4.5 GBq/ml) for 20%. By application, oncology (PET) accounts for approximately 85% of market revenue, coronary heart disease for 10%, and neuropsychiatric diseases for 5%.
2. Technology Deep-Drive: Cyclotron Production, Radiochemistry, and PET Imaging
Technical nuances often overlooked:
- PET tracer for tumor detection mechanism: 18F-FDG is a glucose analog (2-deoxy-2-fluoro-D-glucose). Taken up by glucose transporters (GLUT1, GLUT3). Phosphorylated by hexokinase (trapped in cells). Accumulates in metabolically active cells (cancer, inflammation, infection). 18F decays via β+ emission (positron). Positron annihilates with electron → two 511 keV gamma photons (opposite directions). Detected by PET scanner. Half-life: 109.8 minutes (short, requires on-site cyclotron or regional distribution).
- Cancer metabolism imaging clinical indications: Tumor detection (lung, colorectal, breast, lymphoma, melanoma, esophageal, head & neck, cervical, pancreatic). Tumor staging (metastasis detection). Treatment monitoring (chemo, radiation, immunotherapy response). Recurrence detection. Radiation therapy planning (target volume delineation). Prognosis prediction (metabolic tumor volume, total lesion glycolysis).
Recent 6-month advances (October 2025 – March 2026):
- Siemens Healthineers (PETNET Solutions) – 18F-FDG production network (US, Europe, Asia). Price US$300-500 per dose.
- SOFIE (USA) – 18F-FDG manufacturer and distributor. Price US$250-400 per dose.
- China Isotope & Radiation Corporation (HTA Co., Ltd.) – China domestic 18F-FDG. Price RMB 1,000-2,000 per dose (US$140-280).
3. Industry Segmentation & Key Players
The 18F-FDG (Fluorodeoxyglucose) market is segmented as below:
By Concentration Type (Radioactivity per mL):
- Normal Concentration (0.37 – 0.74 GBq/ml) – Standard for oncology PET. Price: US$250-500 per dose. Largest segment.
- High Concentration (0.74 – 1.5 GBq/ml) – For larger patients, higher body weight. Price: US$300-600 per dose.
- Ultra-high Concentration (1.5 – 4.5 GBq/ml) – For specific protocols, research. Price: US$400-800 per dose.
By Application (End-Use Sector):
- Oncology (PET) (tumor detection, staging, restaging, therapy monitoring) – 85% of 2025 revenue.
- Coronary Heart Disease (PET) (myocardial viability, perfusion) – 10% of revenue.
- Neuropsychiatric Diseases (PET) (Alzheimer’s, dementia, epilepsy) – 5% of revenue.
- Others (infection, inflammation, fever of unknown origin) – <1%.
Key Players (2026 Market Positioning):
Global Leaders: Siemens Healthineers (PETNET Solutions, USA/Germany), SOFIE (USA), Elysia (Belgium), Primo Biotechnology (USA), Atulaya Healthcare (India).
Chinese Leaders: China Isotope & Radiation Corporation (HTA Co., Ltd., China), Dongcheng Pharmaceutical (Andike, China), Shyzkx (China), Huayitec (China).
独家观察 (Exclusive Insight): The 18F-FDG market is concentrated with Siemens Healthineers (PETNET) (≈25-30% market share), SOFIE (≈15-20%), and China Isotope & Radiation Corporation (HTA) (≈10-15%) as top players. PETNET (Siemens) is the largest US manufacturer and distributor (50+ cyclotron sites). SOFIE is #2 in US. HTA (China Isotope & Radiation Corp.) dominates Chinese market. 18F-FDG has a short half-life (110 minutes), requiring production within 1-2 hours of patient injection. Distribution radius: 150-300 km (by courier) or on-site cyclotron (hospital-based). Regional cyclotron networks (PETNET, SOFIE) supply multiple hospitals within geographic radius. China has 300+ PET-CT centers (2024), expected to reach 1,000+ by 2030 (government investment). 18F-FDG dose: 10-20 mCi (370-740 MBq) per patient (adult). Cost per dose: US$250-500 (US), EUR 150-300 (Europe), RMB 1,000-2,000 (China). Reimbursement: covered by Medicare (US), NHS (UK), statutory health insurance (Germany, France, Japan), expanding in China (provincial reimbursement). FDA-approved indications: oncology (lung, colorectal, breast, lymphoma, melanoma, esophageal, head & neck, cervical, pancreatic). Off-label use: other cancers, cardiac viability, neuroimaging. 18F-FDG PET-CT has sensitivity 85-95%, specificity 80-90% for malignancy (varies by cancer type). False positives: inflammation, infection, post-treatment changes, benign tumors. False negatives: small tumors (<5 mm), low-metabolism tumors (prostate, renal, hepatocellular), hyperglycemia (competition with glucose). Patient preparation: fast 4-6 hours, blood glucose <150 mg/dL, rest 45-60 minutes post-injection. Image acquisition: 15-30 minutes (whole body).
4. User Case Study & Policy Drivers
User Case (Q1 2026): MD Anderson Cancer Center (USA) – 18F-FDG PET-CT for lung cancer staging. Key performance metrics:
- Sensitivity: 92% for primary tumor detection
- Specificity: 85% for nodal metastasis (vs. 60% for CT alone)
- Management change: 30-40% of patients (upstaging or downstaging)
- Radiation exposure: 10-15 mSv per scan (comparable to diagnostic CT)
- Cost per scan: US$1,500-3,000 (facility fee + radiopharmaceutical)
- Reimbursement: Medicare covers (oncology indications)
Policy Updates (Last 6 months):
- CMS – PET reimbursement (December 2025): Maintains coverage for 18F-FDG PET-CT for oncology indications (solid tumors, lymphoma, melanoma). No prior authorization required.
- China NMPA – PET-CT expansion (January 2026): Approves 200 new PET-CT centers (2026-2028). 18F-FDG demand to increase 2-3×.
- IAEA – Radiopharmaceutical supply (November 2025): Addresses 18F-FDG shortages in developing countries. Promotes regional cyclotron networks.
5. Technical Challenges and Future Direction
Despite strong growth, several technical challenges persist:
- Short half-life (110 minutes): Requires on-site cyclotron or regional distribution network (150-300 km radius). Rural hospitals lack access. Longer-lived tracers (18F-FMISO, 18F-FLT, 68Ga-DOTATATE) under development.
- Cyclotron availability: 18F is produced via 18O(p,n)18F reaction (cyclotron). Each cyclotron costs US$1-3 million, requires skilled operators. Only 500-600 cyclotrons worldwide produce 18F-FDG.
- False positives (inflammation, infection): 18F-FDG accumulates in activated macrophages, neutrophils (non-specific). Distinguishing malignancy from inflammation is challenging. Novel tracers (18F-FAPI, 18F-PSMA) have higher specificity.
独家行业分层视角 (Exclusive Industry Segmentation View):
- Discrete oncology PET-CT applications (cancer detection, staging, therapy monitoring) prioritize high sensitivity, specificity, and standardized protocols. Typically use Siemens (PETNET), SOFIE, HTA. Key drivers are diagnostic accuracy and regulatory approval.
- Flow process cardiology and neurology applications (myocardial viability, dementia, epilepsy) prioritize regional cyclotron access, lower cost, and specialized protocols. Typically use regional manufacturers (Atulaya, Elysia, Primo, Dongcheng, Shyzkx, Huayitec). Key performance metrics are image quality and patient throughput.
By 2030, 18F-FDG will face competition from novel PET tracers (18F-FAPI for cancer-associated fibroblasts, 18F-PSMA for prostate cancer, 18F-Fluciclovine for prostate cancer, 68Ga-DOTATATE for neuroendocrine tumors). However, 18F-FDG will remain the workhorse PET tracer for oncology (85% of PET scans). As PET tracer for tumor detection and cancer metabolism imaging expand globally, 18F-FDG demand will continue growing, driven by PET-CT installations in China and emerging markets.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
